Rigorous data are sparse concerning the optimal route of administration and dosing strategy for iron therapy with or without concomitant erythropoiesis-stimulating agent ( ESA ) therapy for the management of iron deficiency anaemia in patients with non-dialysis dependent chronic kidney disease ( ND-CKD ) .
